Concern persists over the possible effects of ribavirin exposure on health-care workers. Because personal protective equipment is considered the least appropriate control measure, we devised and evaluated a double-tent system to reduce caregiver exposure.
Materials & Methods
We combined commercially available components (including tent canopy, oxygen hood, tubing, and vacuum units) to provide continuous exhaust and containment of ribavirin aerosol being administered to infants and children up to a weight of about 20 kg while maintaining a stable oxygen concentration. Administrative controls were invoked. Personal-breathing-zone sampling and area sampling were performed during a 5-hour simulation and during an 18-hour treatment period.
Results
No detectable levels of ribavirin were noted. CONCLUSION: These preliminary results suggest that health-care workers can be adequately protected by such controls. However, we emphasize that until further studies are performed using these controls, personal protective equipment should be mandatory for bedside health-care workers.
Get full access to this article
View all access options for this article.
References
1.
Pediatrics American Academy of. Ribavirin therapy of respiratory syncytial virus. Pediatrics1987;79:475–478.
2.
RodriguezWJ, Dang BuiRH, ConnorJD, . Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Anit Agents Chemo1987;31:1143–1146.
3.
FermVH, WillhiteC, KilhamL.Teratogenic effects of ribavirin on hamster and rat embryos. Teratology1978;17:93–102.
4.
KocharDM, PennerJD, KnudsenTB. Embryotoxic, teratogenic and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol1980;52:99–112.
5.
FernandezH, BanksG, SmithR.Ribavirin: A clinical overview. Eur J Epidemiol1986;2:1–14.
6.
HillyardIW. The preclinical toxicology and safety of ribavirin. In: SmithRA, KirkpatrickW, eds. Ribavirin—A wide spectrum agent. New York: Academic Press, 59–71.
7.
KilhamL, FermVH. Congenital anomalies induced in hamster embryos with ribavirin. Science1977;195:413–414.
8.
GuglielmoBJ, JacobsRA, LocksleyRM. The exposure of health care workers to ribavirin aerosol (letter). JAMA1989;261(13):1880–1881.
9.
FacklerJC, FlanneryK, ZipkinM, McIntoshK.Precautions in the use of ribavirin at the Children's Hospital (letter). N Engl J Med1990;322:634.
10.
Labor Occupational Health and Safety Administration. Respiratory protection. Washington DC: 29 CFR 1910:134, Department of.
11.
HarrisonR, BellowJ, RempelD, . Assessing exposures of health-care personnel to aerosols of ribavirin—California. MMWR1988;37:560–562.
12.
GladuJM, EcobichonDJ. Evaluation of exposure of health care personnel to ribavirin. J Toxicol Environ Health1989;28:1–12.
13.
Health California Department of. Health care workers' exposure to ribavirin aerosol. Field Investigation FI-86-009, February 1, 1988.
14.
Agency United States Environmental Protection. Guidelines for the health assessment of suspected developmental toxicants. Federal Register1986;51(185):34028–34040.
15.
CorkeryK, EckmanD, CharneyW.Environmental exposure of aerosolized ribavirin (abstract). Respir Care1989;34:1027.
16.
KrilovLR, JacobsonJM, KarolMS. Containment of environmental escape of aerosolized ribavirin using a double hood system (abstract). Abstracts of the 90th Annual Meeting of the American Society for Microbiology: A115.
